Sharon Benzeno sold $3.5M of ADPT
Chief Commercial Ofc Imm Med at Adaptive Biotechnologies Corp. 165,802 shares at an average of $21.13, traded Jun 26, 2026, filed Jun 30, 2026.
Score components
- +15RoleOfficer
- +25Trade size$3.5M at market
- +20Share of holdings soldSold 58% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001780854-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | MOption exercise Common Stock10b5-1 | +11,034 | $12.14 | $134k | 283,785 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stock10b5-1 | -11,034 | $21.00 | $232k | 272,751 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +1,837 | $12.14 | $22k | 274,588 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +24,944 | $8.46 | $211k | 299,532 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +24,944 | $3.99 | $100k | 324,476 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +51,570 | $8.12 | $419k | 376,046 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stock10b5-1 | -154,768 | $21.14 | $3.3M | 221,278 | Jun 30, 2026 |
| Jun 26, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,034 | $0.00 | $0 | 1,837 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,837 | $0.00 | $0 | 0 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -24,944 | $0.00 | $0 | 37,416 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -24,944 | $0.00 | $0 | 87,303 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -51,570 | $0.00 | $0 | 113,457 | Jun 30, 2026 |
Related signals
Other insiders at Adaptive Biotechnologies Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $948k 35,643 shares | -9% | |
| Pro nowfree Oct 15, 2026 | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $193k 6,444 shares | -2% | |
| 22Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $758k 26,792 shares | -11% | |
| 25Weak | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $1.0M 35,643 shares | -9% | |
| 23Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $3.2M 115,406 shares | -34% | |
| 8Weak | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $32k 1,195 shares | -0% | |
| 48Moderate | Adaptive Biotechnologies Corp | Katey Einterz Owen director | $250k 9,615 shares | -11% | |
| 46Moderate | Adaptive Biotechnologies Corp | Robert Hershberg director | $748k 30,664 shares | -40% | |
| 50Moderate | Adaptive Biotechnologies Corp | Peter M Neupert director | $3.1M 124,690 shares | -49% | |
| 55Moderate | Adaptive Biotechnologies Corp | Chad M Robins CEO and Chairman | $15M 600,000 shares | -24% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.